Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Publication/Presentation Date
6-15-2016
Abstract
Anemic patients remain at increased risk of ischemic and bleeding events. Whether the effects of hemoglobin levels on thrombotic and bleeding risk are independent of platelet reactivity on clopidogrel, however, remains unknown. Patients from the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents study were categorized by the presence of anemia at baseline, defined according the World Health Organization criteria. Platelet reactivity was measured with VerifyNow assay; high platelet reactivity (HPR) on clopidogrel was defined as platelet reactive units value >208. Of 8,413 patients included in the study cohort, 1,816 (21.6%) had anemia. HPR was more prevalent in patients with anemia (58.3% vs 38.4%; p
Volume
117
Issue
12
First Page
1877
Last Page
1883
ISSN
1879-1913
Published In/Presented At
Giustino, G., Kirtane, A. J., Baber, U., Généreux, P., Witzenbichler, B., Neumann, F., & ... Stone, G. W. (2016). Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology, 117(12), 1877-1883. doi:10.1016/j.amjcard.2016.03.034.
Disciplines
Medicine and Health Sciences
PubMedID
27131611
Department(s)
Department of Medicine, Cardiology Division, Department of Medicine Faculty
Document Type
Article